Shippeo Launches Second Edition of Visibility Now!, the Premier Event for Supply Chain & Transportation Visibility
10.11.2021 11:15:00 EET | Business Wire | Press release
Shippeo, a global leader and European specialist in real-time transportation visibility, has announced the second edition of its customer community event Visibility Now! in partnership with Savoye, TESISQUARE®, and Siemens Digital Logistics. The hybrid event will take place both online and in-person in Paris on November 17 and offer a unique experience for all participants no matter where they are. From keynotes to customer testimonials and workshops and expert sessions, participants will have the chance to discover product insights and benefit from the expert’s points of view.
With covid border restrictions, container and driver shortages as well as the recent Suez Canal obstruction, now is the time for organizations to build resilient supply chains and visibility as a key enabler.
The event will include speakers from leading international organizations who will share their experiences on working with visibility solutions, outlining the critical roles they play in their digital transformation initiatives, and covering topics such as supply chain automation, global supply chain management, customer-centric approach and product innovation. Participants will have the opportunity to:
- Hear industry leaders discuss their experiences and best practices, including speakers from Renault Group, Coca-Cola HBC, DHL Freight, Nexans, Leroy Merlin, Philip Morris International, and Magnus Logistics
- Listen to top experts covering the latest trends, innovations, and guidelines to ensure transportation visibility project success such as Dr. John Gattorna, Siemens Digital Logistics, Savoye and TESISQUARE®
- Enjoy complimentary access to exclusive recorded sessions to dive deeper into trending topics on supply chain management and visibility
- Meet and engage with Shippeo’s team, alongside other Shippeo users and industry peers throughout the day
Global Supply Chain thought leader, Dr. John Gattorna, will share insights on designing future supply chains with embedded resilience, the challenges of operating global supply chain networks, and embracing multi-modal transportation as an integral part of future supply chains. He will also touch on the future role of 3PLs and 4PLs as genuine partners in the extended supply chain.
The event will include a live 90-minute plenary live show, broadcast from Paris in a dynamic and interactive format where participants will discover the latest insights, trends, and innovations related to supply chain and transportation visibility across a number of industry sectors. Several workshops and expert sessions will be held on demand for a deep dive into trending topics and best practices. These interactive workshops will provide an opportunity for participants to interact with other market leaders facing similar challenges and hear more about the latest news, insights, and product innovations in supply chain and transportation visibility from Shippeo experts.
“In the midst of supply chain disruptions, businesses have come to realize the value of real-time visibility and the need to take action, and further engage in digital transformation processes. We’re delighted to showcase the must-attend transportation visibility event and offer participants a place where they can hear from top industry experts, interact with other shippers, carriers, and logistics service providers from across the ecosystem to share and discover new ways to leverage visibility,” says Lucien Besse, COO of Shippeo.
The live show will stream from 1.30 pm on Wednesday 17th November. More information about the agenda, speakers, and how to register for the free event is available at shippeo.com/visibilitynow
About Shippeo
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 850+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Over 100 customers, including global brands like Coca-Cola HBC, Carrefour, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 25 million shipments per year across 74 countries. Learn more at www.shippeo.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005610/en/
Contact information
Audrey Emanuel, audrey.emanuel@shippeo.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release
Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 17:13:00 EEST | Press release
For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and more practical: what it takes to make a specific, high-stakes determination reliable, fast and affordable at scale. A vertical, domain-focused process, gro
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 17:08:00 EEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom